SCHEMBL24007232

SCHEMBL24007232

ClCc1cc(C2CCC2)no1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.36
IGF1R P08069 4/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
PSMB8 P28062 1/20 0.33
PSMB9 P28065 1/20 0.33
PSMB5 P28074 1/20 0.33
FGFR1 P11362 1/20 0.33
KDR P35968 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
CCR5 P51681 1/20 0.31
S1PR3 Q99500 5/20 0.31
S1PR1 P21453 3/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
XBP1 P17861 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20163165 0.95 IGF1R (0.40) MAPK14IGF1RDRD2DRD4DRD3
SCHEMBL9270768 0.92 IGF1R (0.36) MAPK14IGF1RDRD2DRD4DRD3
SCHEMBL3931966 0.81 NOTUM (0.43) MAPK14IGF1RDRD2DRD4DRD3
SCHEMBL9629513 0.81 NOTUM (0.43) MAPK14IGF1RDRD2DRD4DRD3
SCHEMBL9629655 0.78 NOTUM (0.43) MAPK14IGF1RPSMB8PSMB9PSMB5
SCHEMBL15109557 0.76 NOTUM (0.42) IGF1RPSMB8PSMB9PSMB5CHRNB2
SCHEMBL9628686 0.76 NOTUM (0.42) IGF1RPSMB8PSMB9PSMB5CHRNB2
SCHEMBL11613001 0.76 IGF1R (0.40) IGF1RPSMB8PSMB9PSMB5FGFR1
SCHEMBL9629417 0.73 NOTUM (0.46) MAPK14IGF1RDRD2DRD4DRD3
SCHEMBL442114 0.73 NOTUM (0.46) IGF1RDRD2DRD4DRD3FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542278-B1 Heteroaromatic macrocyclic ether chemotherapeutic agents NUVALENT, INC. (US) 2023-01-03 US disclosed
WO-2021226208-A2 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT, INC. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542278-B1 Heteroaromatic macrocyclic ether chemotherapeutic agents CYP2C8, ABCB1, CYP3A43 MAPK14 2809/4885IGF1R 3318/4885DRD2 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.